Atlas Trials

HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a)

Clinical trial NCT04257162 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04257162
Sponsor
SOLTI Breast Cancer Research Group
Status
ACTIVE_NOT_RECRUITING
Phase
Not Applicable
Study type
INTERVENTIONAL
Metastatic Cancer
Start date
2019-12-13
Primary completion
2025-06-30
Enrollment
180

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.